Myriad Genetics said updated NCCN oncology guidelines revise genetic high-risk assessment for colorectal and gastric cancers. The June 16 update also covers end

Myriad Genetics said updated NCCN oncology guidelines revise genetic high-risk assessment for colorectal and gastric cancers. The June 16 update also covers endometrial and esophageal cancers, extending the company’s push in risk-evaluation tools.